Invesaro

Stocks DRTS Financial statements

Financial statements

Alpha Tau Medical Ltd. financial statements

Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Alpha Tau Medical Ltd. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2019FY2021FY2021FY2022FY2023FY2024FY2025
Research and development6.647.5411.420.926.42732.1
General and administrative0.981.411.8610.37.336.678.36
Operating income8.01-9.24-13.8-32.1-35.7-36-42.3
Interest expense0.080.30.35
Other non-operating income-13.5-1.616.544.3-0.22
Pre-tax income8.32-8.72-27.3-33.7-29.1-31.7-42.5
Income tax-0.150.160.010.020.020.010.12
Income from continuing operations-8.37-8.88-27.3-33.8
Net income to minority interests-0.1
Net income-8.37-8.88-27.3-33.8-29.2-31.8-42.6
EBITDA8.08-9.16-13-31.2-34.6-34.9-41.1
EPS, basic-0.25-0.22-0.67-0.53-0.42-0.45-0.53
EPS, diluted-0.25-0.22-0.67-0.53-0.42-0.45-0.53
Shares, basic (weighted)33.840.340.563.569.469.980.6
Shares, diluted (weighted)33.840.340.563.569.469.980.6

Balance sheet

FY2019FY2021FY2021FY2022FY2023FY2024FY2025
Cash and equivalents1.8415.623.25.8412.713.712.2
Short-term investments8.0898.769.145.960.9
Other current assets0.860.711.10.821.371.4
Total current assets47.532.610685.864.278.3
Property, plant and equipment5.47.557.4712.813.919.7
Lease right-of-use assets5.818.367.617.21
Total assets5342.212010786.2106
Accounts payable0.961.21.422.573.533.87
Accrued liabilities0.552.371.282.242.623.78
Total current liabilities2.094.414.347.18.6810.5
Lease liabilities4.526.65.966.24
Total liabilities7.452314.522.923.528.6
Paid-in capital17.118.1192200210267
Retained earnings-25.6-52.8-86.6-116-148-190
Shareholders' equity-0.19-8.43-34.810684.562.777.1
Total equity-0.19-8.43-34.810684.562.777.1
Total liabilities and equity5342.212010786.2106
Shares outstanding40.440.569.169.770.488

Cash flow statement

FY2019FY2021FY2021FY2022FY2023FY2024FY2025
Net income8.468.8827.3-33.8-29.2-31.8-42.6
Depreciation and amortization0.070.090.780.981.071.11.23
Stock-based compensation0.550.60.816.757.939.9210.6
Deferred income tax0.1
Cash from operations-6.91-7.25-11.8-23.9-18-19.8-26.7
Capital expenditures-1.29-3.77-2.93-0.9-6.4-2.24-6.08
Purchases of investments-70.2-8.08-121-164-125-70.5
Cash from investing-10.2-7.8219.3-89.918.720.8-20.6
Debt issued5.25
Stock issued0.020.110.030.050.0345.5
Cash from financing5.3229.30.1196.95.30.0345.8
Exchange rate effect-0.020.080.11-0.26-0.050.06-0.02
Net change in cash-11.814.37.68-17.25.971.07-1.52
Free cash flow-8.2-11-14.7-24.8-24.4-22-32.8
Interest paid0.780.540.350.240.050.320.38
Income taxes paid000.010.020.010

Key metrics

Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $14.54 on September 25, 2026.

Profitability

MetricValueHow it is calculated
Return on equity (ROE)-61.0%Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)-44.4%Net income / average total assets.
Return on invested capital (ROIC)-58.7%Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.

Growth

MetricValueHow it is calculated
Book value growth, 1y23.0%Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y-10.0%Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y22.6%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y-4.2%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y14.8%Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y15.2%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y8.2%Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y14.9%Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Current ratio7.45xCurrent assets / current liabilities.
Quick ratio6.96x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio6.96x(Cash + short-term investments) / current liabilities.
Liabilities / assets27.0%Total liabilities / total assets.
Interest coverage-122xOperating income / interest expense.
Working capital$67.8MCurrent assets - current liabilities.
Tangible book value$77.1MShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted-$0.53Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic-$0.53Net income per basic share, as reported (split-adjusted).
FCF per share-$0.41Free cash flow / diluted weighted shares.
Operating cash flow per share-$0.33Cash from operations / diluted weighted shares.
Book value per share$0.88Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share$0.88Tangible book value / shares outstanding.
Cash per share$0.83(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$1.34BShare price x shares outstanding.
Enterprise value$1.27BMarket cap + total debt - cash - short-term investments.
P/B17.4xMarket cap / shareholders' equity. Only when equity is positive.
Price / tangible book17.4xMarket cap / tangible book value, when positive.
FCF yield-2.4%Free cash flow / market cap.
Earnings yield-3.2%Net income / market cap (the inverse of P/E).
Was Alpha Tau Medical Ltd. profitable in fiscal 2025?

No. It reported a net loss of $42.6M.

How much free cash flow did Alpha Tau Medical Ltd. generate in fiscal 2025?

Cash from operations of $26.7M minus capital expenditures of $6.1M left free cash flow of -$32.8M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Alpha Tau Medical Ltd.